Posted by Michael Wonder on 25 Dec 2025
Korea to expand Keytruda reimbursement to 11 new cancer uses starting 2026
24 December 2025 - Korea’s national health insurance program will broaden reimbursement for MSD’s blockbuster PD-1 inhibitor Keytruda in a wide ranging decision that adds 11 new covered uses across head and neck, gastric, breast, gynaecologic and biomarker-defined gastro-intestinal cancers.
MSD Korea said the country’s Health Insurance Policy Deliberation Committee on Tuesday approved the expansion, with coverage set to begin 1 January 2026.
